Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Collplant Holdings ( (CLGN) ) is now available.
On August 20, 2025, CollPlant Biotechnologies reported its financial results for the second quarter of 2025, highlighting significant advancements in its photocurable dermal filler program and regenerative breast implant technology. The company is preparing for clinical studies of its dermal filler, which has shown promising results in preclinical testing, and is expanding its market presence with new appointments and collaborations. CollPlant also reported a decrease in GAAP revenues for the quarter compared to the previous year, but an increase in revenues for the first half of the year due to a milestone payment from AbbVie. The company’s efforts to expand its product distribution and enhance its market position in the regenerative medicine industry are ongoing, with a focus on non-animal-derived collagen solutions.
The most recent analyst rating on (CLGN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
Collplant Holdings’ overall score is primarily impacted by its weak financial performance, with significant revenue and cash flow challenges. Technical analysis provides some positive momentum signals, though these are counterbalanced by valuation concerns, particularly the negative P/E ratio. The lack of earnings call and corporate event data limits additional insights.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetics medicine company based in Israel, specializing in innovative technologies and products derived from non-animal rhCollagen for tissue regeneration and medical aesthetics. The company focuses on developing dermal fillers, regenerative breast implants, and bioinks for various medical applications, aiming to provide safer and more effective alternatives in the medical aesthetics and regenerative medicine markets.
Average Trading Volume: 127,084
Technical Sentiment Signal: Sell
Current Market Cap: $33.82M
See more data about CLGN stock on TipRanks’ Stock Analysis page.